查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858090

胃轻瘫治疗市场按产品类型、药物类别、给药途径、分销管道和最终用户划分 - 全球预测 2025-2032

Gastroparesis Drugs Market by Product Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，胃轻瘫药物市场规模将达到 79.7 亿美元，复合年增长率为 7.30%。

关键市场统计数据
基准年 2024 45.4亿美元
预计年份：2025年 48.7亿美元
预测年份 2032 79.7亿美元
复合年增长率 (%) 7.30%

本书对胃轻瘫的临床复杂性、治疗限制以及影响治疗格局的商业性因素进行了精准而权威的介绍。

胃轻瘫治疗领域的特点是临床表现复杂，患者需求尚未被满足，且药物治疗方法既有传统疗法也有新兴疗法。患者症状差异很大，现有药物难以有效应对，临床医师需要在长期治疗过程中权衡疗效、安全性和耐受性。在此背景下，产业参与者面临着监管审查、成本压力以及证明病患报告结局显着改善的挑战。

本报告简明扼要地说明了影响胃轻瘫药物的临床和商业性环境。报告检验了药物类别、给药方式、通路以及最终用户因素如何影响医院、诊所和居家医疗的用药。透过整合最新的临床证据、供应链和政策趋势，引言部分为后续的详细分析奠定了基础，使决策者能够在更广泛的治疗和营运框架内做出战术性选择。

对影响胃轻瘫治疗和商业化策略的科学、监管和商业性变革进行简要概述

近年来，胃轻瘫的治疗模式发生了显着变化，这主要得益于药物研发趋势、以患者为中心的监管环境以及新型给药技术的成熟。製药公司越来越重视针对特定机制路径以改善胃动力并减轻全身副作用的分子。同时，口服生物製药技术和经皮给药概念的成熟也拓宽了临床医师可用的药物套件，使其能够提供超越简单疗效声明的差异化提案主张。

在商业性，製药业正经历专科药物研发商、契约製造和学名药生产商之间的策略整合。这加速了现有药物的生命週期管理策略，透过重新配方和新的给药途径来延长其临床效用。同时，支付方和医疗服务提供方正转向基于价值的合约和基于结果的报销模式，提高了证据生成和长期安全性监测的标准。这些因素共同作用，正在重塑打入市场策略、临床试验设计和商业化路径，并将继续影响整个行业的投资重点和合作模式。

对 2025 年美国关税上调如何加剧胃轻瘫治疗药物供应链网络中的供应链、采购和定价动态进行分析性回顾。

美国高额关税的实施，为全球原料药供应链和筹资策略带来了额外的限制和复杂性，尤其对于那些依赖进口原料药和成品药的药品而言更是如此。过去透过跨境原料药采购优化成本的生产网络，如今不得不重新评估供应商合格、缓衝库存策略以及近岸外包的可行性，以缓解关税造成的成本波动。同时，各公司也正在调整与研发和製造外包的合约条款，以分担或承担增加的成本负担。

在营运方面，不断上涨的进口关税促使医院药房、专科药品经销商和零售通路重新审视库存策略，许多机构延长前置作业时间并实现供应商多元化，以确保供应的连续性。临床医生和采购负责人可能会面临短期价格压力，这会影响处方模式，尤其是在存在多种治疗方案的情况下。此外，关税主导的成本上涨可能会限制製造商为后期临床试验和配方改良倡议提供资金的灵活性，因为资金需要重新分配以确保生产和合规性。最终，这些累积效应将凸显增强韧性的措施的重要性，例如投资区域生产、建立策略性原料药储备以及加强品质监管，以在日益加强保护主义的环境下维持产品的供应和患者的用药便利。

多维度的细分视角揭示了产品类型、治疗层级、给药途径、管道和最终用户如何以独特的方式影响临床应用和商业策略。

细分市场分析揭示了产品类型、药物类别、给药途径、分销管道和最终用户等方面的差异化动态，这些因素共同影响治疗方法的采纳和商业性化进程。根据产品类型，可区分品牌学名药。品牌药通常以针对性的临床数据和生命週期延长策略为支撑，而仿製药则更注重成本效益和处方渗透率。这些截然不同的动态为生产商带来了不同的奖励：品牌药开发商优先考虑差异化和证据深度，而学名药学名药则更注重生产规模和通路优化。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 新型Ghrelin受体促效剂的应用日益增多，这些激动剂可改善难治性胃轻瘫患者的胃动力
  • 非侵入性胃电刺激设备在门诊治疗糖尿病胃轻瘫症状的新应用
  • 开发甲氧氯普胺缓释製剂，以最大限度地减少长期治疗期间对中枢神经系统的副作用。
  • 增加针对多种受体路径口服小分子促动力药物的投资，以克服现有疗法的局限性
  • 整合来自病患登记的真实世界证据，以支持高成本胃轻瘫生物製药的报销。
  • 扩大管线研究，评估促效剂和胃动素类似物联合治疗的协同促动力作用

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的胃轻瘫治疗市场

  • 品牌
  • 学名药

9. 胃轻瘫药物市场（依药物类别划分）

  • 多巴胺拮抗剂
    • 西沙必利
    • 多潘立酮
    • 甲氧氯普胺
  • 胃动素受体促效剂
    • 阿奇霉素
    • 红霉素
  • 血清素受体促效剂
    • Granisetron
    • Ondansetron

10. 依给药途径分類的胃轻瘫药物市场

  • 注射
  • 口服
  • 经皮

第十一章 胃轻瘫药物市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 胃轻瘫治疗市场（依最终用户划分）

  • 诊所
  • 居家照护
  • 医院

13. 各地区胃轻瘫药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 胃轻瘫药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国胃轻瘫药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Sandoz International GmbH
    • Sun Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Johnson & Johnson
    • AbbVie Inc.
    • Ironwood Pharmaceuticals, Inc.
    • Motus GI Holdings, Inc.
    • Pfizer Inc.
Product Code: MRR-C002B1C996F5

The Gastroparesis Drugs Market is projected to grow by USD 7.97 billion at a CAGR of 7.30% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.54 billion
Estimated Year [2025] USD 4.87 billion
Forecast Year [2032] USD 7.97 billion
CAGR (%) 7.30%

A precise and authoritative introduction framing clinical complexity, treatment limitations, and commercial considerations shaping the gastroparesis therapeutic landscape

The therapeutic arena for gastroparesis is characterized by persistent clinical complexity, unmet patient needs, and a mix of legacy and evolving pharmacologic approaches. Patients experience a broad spectrum of symptoms that can be difficult to manage with existing options, while clinicians balance efficacy, safety, and tolerability in long-term care pathways. Against this backdrop, industry players are navigating regulatory scrutiny, cost pressures, and the imperative to demonstrate meaningful improvements in patient-reported outcomes.

This report provides a concise orientation to the clinical and commercial context shaping gastroparesis drugs. It examines drug class dynamics, delivery modalities, distribution pathways, and end-user considerations that influence adoption in inpatient, clinic, and home care settings. By integrating recent clinical evidence with supply chain and policy developments, the introduction sets the stage for deeper analyses that follow, enabling leaders to contextualize tactical choices within a broader therapeutic and operational framework.

A concise synthesis of the transformative scientific, regulatory, and commercial shifts reshaping gastroparesis therapeutics and commercialization strategies

Recent years have seen transformative shifts in the gastroparesis landscape driven by advances in drug development, regulatory focus on patient-centered endpoints, and the maturation of alternative delivery technologies. Pharmaceutical innovators are increasingly prioritizing molecules that target specific mechanistic pathways to improve gastric motility while mitigating systemic adverse effects. Concurrently, the maturation of oral-biologic formulation techniques and transdermal delivery concepts has broadened the pharmacologic toolkit available to clinicians, enabling differentiated value propositions beyond simple efficacy claims.

Commercially, the industry is experiencing strategic convergence between specialty developers, contract manufacturers, and generic producers. This has accelerated lifecycle management strategies for established agents through reformulation and new routes of administration that extend clinical utility. At the same time, payers and providers are shifting toward value-based contracting and outcome-aligned reimbursement, raising the bar for evidence generation and long-term safety monitoring. These combined forces are reshaping market entry strategies, clinical trial design, and commercialization pathways, and they will continue to influence investment priorities and partnership models across the sector.

An analytical review of how elevated U.S. tariffs in 2025 have amplified supply chain, procurement, and pricing dynamics across gastroparesis drug supply networks

The imposition of elevated tariffs in the United States has introduced a conditional layer of complexity into global pharmaceutical supply chains and procurement strategies, particularly for agents reliant on imported active pharmaceutical ingredients and finished dosage forms. Manufacturing networks that previously optimized cost through cross-border API sourcing must now re-evaluate supplier qualification, buffer inventory policies, and nearshoring feasibility to mitigate tariff-driven cost volatility. In parallel, firms are recalibrating contractual terms with contract development and manufacturing organizations to share or absorb incremental cost burdens, which in turn affects pricing negotiations with distributors and downstream payers.

Operationally, increased import levies have prompted a reassessment of inventory strategies for hospital pharmacies, specialty distributors, and retail channels, with many organizations extending lead times and diversifying supplier bases to protect continuity of supply. Clinicians and procurement officers may experience short-term pricing pressure that influences prescribing patterns, particularly where multiple therapeutic alternatives exist. Furthermore, tariff-driven cost increases can constrain manufacturers' flexibility to finance late-stage clinical programs or reformulation initiatives, as capital is reallocated toward ensuring uninterrupted production and compliance. Ultimately, the cumulative impact emphasizes resilience-building measures-regional manufacturing investments, strategic API stockpiles, and tightened quality oversight-to maintain product availability and preserve patient access in an increasingly protectionist trade environment.

A multi-dimensional segmentation lens revealing how product types, therapeutic classes, delivery routes, channels, and end users uniquely influence clinical adoption and commercial strategy

Segmentation analysis reveals differentiated dynamics across product type, drug class, route of administration, distribution channel, and end user that collectively shape therapeutic adoption and commercial execution. Based on Product Type, the landscape distinguishes branded therapies from generics, with branded agents typically anchored by targeted clinical data and lifecycle-extension strategies while generics emphasize cost-efficiency and formulary penetration. These opposing dynamics create distinct incentives for manufacturers: branded developers prioritize differentiation and evidence depth, whereas generic producers focus on manufacturing scale and channel optimization.

Based on Drug Class, the market is studied across Dopamine Antagonists, Motilin Receptor Agonists, and Serotonin Receptor Agonists. The Dopamine Antagonists is further studied across Cisapride, Domperidone, and Metoclopramide, where safety profiles and regulatory legacies govern prescribing limitations and monitoring requirements. The Motilin Receptor Agonists is further studied across Azithromycin and Erythromycin, which offer prokinetic properties but raise concerns about antimicrobial stewardship and long-term tolerability. The Serotonin Receptor Agonists is further studied across Granisetron and Ondansetron, which are primarily utilized for symptom control in specific care settings and may be repurposed or reformulated to enhance delivery. Differentiation across these classes is shaped not only by mechanism of action but also by demonstrable effects on patient-relevant endpoints, regulatory labeling, and long-term safety evidence.

Based on Route Of Administration, the market is studied across Injectable, Oral, and Transdermal approaches, each presenting distinct development and commercialization considerations. Injectable options can offer rapid onset and consistent pharmacokinetics but require clinical settings for administration and introduce cold-chain and device complexities. Oral formulations remain the most practicable for chronic outpatient management, yet they face bioavailability and tolerability constraints that drive reformulation efforts. Transdermal delivery presents an avenue for steady-state exposure and improved adherence but requires investment in device compatibility and robust skin tolerability data.

Based on Distribution Channel, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, and channel selection influences reimbursement complexity, patient access pathways, and the economics of specialty versus commodity products. Hospital pharmacies often manage inpatient and acute therapeutic needs and may drive early adoption of novel therapies supported by hospital formularies and therapeutic committees. Online pharmacies have emerged as critical access points for chronic management, where convenience and continuity of supply are weighed against regulatory controls and quality assurance. Retail pharmacies remain central to community-based dispensing and play a pivotal role in patient counseling and adherence support.

Based on End User, the market is studied across Clinics, Home Care Settings, and Hospitals, each shaping the clinical use case and service model for gastroparesis therapies. Clinics frequently manage ambulatory patients requiring ongoing symptomatic management and titration, whereas home care settings demand simplified administration, adherence-support solutions, and remote monitoring capabilities. Hospitals manage acute presentations and complex comorbidities and often influence adoption through institutional protocols and multidisciplinary care pathways. Understanding these segmentation layers helps stakeholders align clinical evidence, pricing strategies, and distribution mechanisms to the distinct needs of each subgroup, thereby informing targeted development and commercialization plans.

A strategic regional analysis illuminating how Americas, Europe, Middle East & Africa, and Asia-Pacific differences impact access, regulation, and commercialization of gastroparesis treatments

Regional dynamics exert a pronounced influence on access pathways, regulatory expectations, and commercial models across the gastroparesis space. In the Americas, incentives for innovation coexist with intense payer scrutiny and diverse reimbursement landscapes that drive differentiated go-to-market tactics and value demonstration requirements. Clinical practice variation across the Americas also shapes formulary selection and the relative uptake of novel versus established agents, while supply chain resilience remains a central operational priority.

In Europe, Middle East & Africa, fragmented regulatory frameworks and heterogeneous payer systems necessitate adaptive market entry strategies that account for localized pricing negotiations, health technology assessment processes, and varying levels of specialist availability. Countries within this expansive region may prioritize different evidence standards or access pathways, creating opportunities for targeted demonstration projects and early-access agreements. In Asia-Pacific, dynamic growth in healthcare infrastructure, expanding specialty care capacity, and rising patient awareness combine to present both opportunity and complexity. Policymakers and providers in Asia-Pacific are increasingly receptive to models that enhance outpatient management and remote-care delivery, which supports the adoption of oral and transdermal innovations. Across all regions, strategic emphasis on supply chain redundancy, regulatory alignment, and evidence generation tailored to local decision-making frameworks is essential for sustained success.

An incisive corporate overview describing how innovation, alliances, and operational resilience are redefining competitive strategies among gastroparesis drug developers

Company-level behavior in the gastroparesis domain reflects a balance between innovation, lifecycle management, and operational efficiency. Innovator firms continue to invest in targeted mechanisms that promise improved efficacy or tolerability, often coupling clinical development with biomarker strategies and patient-reported outcome measures to substantiate differentiated value. At the same time, specialty and generics manufacturers deploy cost and supply advantages to capture clinical segments where established products remain clinically acceptable.

Strategic alliances-spanning licensing, codevelopment, and contract manufacturing-have become common as firms seek to accelerate time-to-market while controlling development cost and complexity. Firms with integrated manufacturing footprints or strong partnerships with contract organizations are better positioned to absorb trade-related disruptions or to pursue regional production. Additionally, companies are increasingly investing in digital therapeutics adjuncts, remote monitoring, and adherence platforms that complement pharmacologic therapy and provide richer real-world evidence. Collectively, these company-level strategies indicate a pragmatic shift toward collaborative, patient-focused, and operationally resilient business models that sustain long-term competitive advantage.

Practical and prioritized recommendations for industry leaders to strengthen evidence generation, supply resilience, and value-based adoption for gastroparesis therapies

Leaders seeking to secure advantage in gastroparesis therapeutics should prioritize evidence frameworks that demonstrate patient-centered outcomes and real-world effectiveness. Early investment in patient-reported outcome measures, long-term safety registries, and pragmatic trial designs will strengthen value propositions for payers and providers and support differentiated positioning versus incumbent therapies. Strategic collaboration with clinicians and patient advocacy networks can accelerate meaningful endpoint selection and uptake while enriching post-launch data capture.

Operationally, companies should diversify supply chains and evaluate selective nearshoring or regional manufacturing options to mitigate tariff sensitivity and procurement disruption. Investing in digital adherence tools and companion care models will increase the stickiness of therapies delivered in home care and outpatient settings, and these adjuncts can be leveraged to generate ongoing real-world evidence. Finally, pricing strategies must be aligned with demonstrated clinical value, with alternative contracting models considered where outcomes can be reliably measured and validated. Taken together, these measures enable firms to balance access, affordability, and innovation in a rapidly evolving therapeutic and policy landscape.

A transparent and rigorous methodological summary describing how secondary research and targeted primary interviews were triangulated to produce validated insights for stakeholders

The research methodology underpinning this analysis combined systematic secondary research with targeted primary data collection to ensure both breadth and depth of evidence. Secondary sources included peer-reviewed clinical literature, regulatory guidance documents, and publicly available corporate disclosures, which were synthesized to map therapeutic mechanisms, safety profiles, and regulatory precedents. This foundation was augmented by primary interviews with clinical specialists, supply chain executives, and reimbursement experts to capture real-time perspectives on access barriers, prescribing behavior, and procurement dynamics.

Data synthesis followed a triangulation process to reconcile divergent perspectives and to validate trends across independent sources. Qualitative insights were coded thematically to identify recurring strategic imperatives and operational constraints, while cross-regional comparisons highlighted contextual differences relevant to market entry and commercialization. Limitations include variability in regional data transparency and the evolving nature of trade policy and clinical evidence, which were explicitly accounted for through sensitivity checks and stakeholder validation sessions. The methodology thus balances rigor and pragmatism, delivering actionable intelligence grounded in multi-stakeholder evidence.

A clear and strategic conclusion that synthesizes clinical promise, commercial imperatives, and operational resilience required for successful gastroparesis program execution

In sum, the gastroparesis therapeutic environment is at an inflection point where scientific progress, policy shifts, and operational realities converge to redefine value creation. Advances in targeted pharmacology and delivery technologies offer genuine promise for improved patient outcomes, yet clinical adoption will depend on compelling evidence, payer alignment, and practical administration models that meet the needs of ambulatory and home care settings. Simultaneously, macro-level pressures such as tariffs and supply chain fragility underscore the importance of resilience and strategic sourcing in maintaining patient access and commercial viability.

The path forward requires integrated strategies that couple robust evidence generation with pragmatic operational planning. Firms that align clinical differentiation with resilient manufacturing, flexible distribution models, and outcome-focused contracting will be best positioned to create sustainable impact for patients and stakeholders alike. The insights compiled here provide a strategic foundation for leaders to refine development priorities, optimize commercial paths, and mitigate policy and supply risks as they pursue durable therapeutic and business outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of novel ghrelin receptor agonists demonstrating improved gastric motility in refractory gastroparesis patients
  • 5.2. Emerging use of noninvasive gastric electrical stimulation devices for outpatient management of diabetic gastroparesis symptoms
  • 5.3. Advancements in formulation of sustained release metoclopramide to minimize central nervous system side effects in long term therapy
  • 5.4. Rising investment in oral small molecule prokinetics targeting multiple receptor pathways to overcome current therapeutic limitations
  • 5.5. Integration of real world evidence from patient registries to support reimbursement of high cost gastroparesis biologic therapies
  • 5.6. Expansion of pipeline trials assessing combination therapies of serotonergic and motilin analogs for synergistic prokinetic effects

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastroparesis Drugs Market, by Product Type

  • 8.1. Branded
  • 8.2. Generics

9. Gastroparesis Drugs Market, by Drug Class

  • 9.1. Dopamine Antagonists
    • 9.1.1. Cisapride
    • 9.1.2. Domperidone
    • 9.1.3. Metoclopramide
  • 9.2. Motilin Receptor Agonists
    • 9.2.1. Azithromycin
    • 9.2.2. Erythromycin
  • 9.3. Serotonin Receptor Agonists
    • 9.3.1. Granisetron
    • 9.3.2. Ondansetron

10. Gastroparesis Drugs Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Transdermal

11. Gastroparesis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Gastroparesis Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care Settings
  • 12.3. Hospitals

13. Gastroparesis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gastroparesis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gastroparesis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Teva Pharmaceutical Industries Ltd.
    • 16.3.2. Viatris Inc.
    • 16.3.3. Sandoz International GmbH
    • 16.3.4. Sun Pharmaceutical Industries Ltd.
    • 16.3.5. Dr. Reddy's Laboratories Ltd.
    • 16.3.6. Johnson & Johnson
    • 16.3.7. AbbVie Inc.
    • 16.3.8. Ironwood Pharmaceuticals, Inc.
    • 16.3.9. Motus GI Holdings, Inc.
    • 16.3.10. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GASTROPARESIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. GCC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GCC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GCC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. GCC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 320. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 321. GCC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 322. GCC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 323. GCC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION